Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
about
Weight management in obesity - past and presentObesity pharmacotherapy: current perspectives and future directionsInhibitors of pancreatic lipase: state of the art and clinical perspectivesNew and emerging drug molecules against obesity.New advances in models and strategies for developing anti-obesity drugs.Acute lipotoxicity regulates severity of biliary acute pancreatitis without affecting its initiationObesity pharmacotherapy: what is next?Safety of antiobesity drugs.The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agentsWeight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).Pharmacotherapy for childhood obesity: present and future prospects.Comparative efficiency and safety of pharmacological approaches to the management of obesity.Current pharmacotherapeutic concepts for the treatment of obesity in adults.Drugs in the pipeline for the obesity market.RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models.Pharmacological treatment of obesity in children and adolescents: current status and perspectives.Effects of surfactants on lipase structure, activity, and inhibition.Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.Do we need anti-obesity drugs?Peripheral targets in obesity treatment: a comprehensive update.Tolerability and safety of the new anti-obesity medications.Horizons in the Pharmacotherapy of Obesity.Epidemiology of Obesity and Pharmacologic Treatment Options.Dinapinones, novel inhibitors of triacylglycerol synthesis in mammalian cells, produced by Penicillium pinophilum FKI-3864.Fungal endophytes associated with Viola odorata Linn. as bioresource for pancreatic lipase inhibitors.Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.New isochaetochromin, an inhibitor of triacylglycerol synthesis in mammalian cells, produced by Penicillium sp. FKI-4942: I. Taxonomy, fermentation, isolation and biological properties.Identification of 1H-indene-(1,3,5,6)-tetrol derivatives as potent pancreatic lipase inhibitors using molecular docking and molecular dynamics approach.Gold-catalyzed formal [4π + 2π]-cycloadditions of propiolate derivatives with unactivated nitriles.
P2860
Q26774747-3D653E58-CE7D-4035-AB16-B9B14059E7F2Q26828559-0501EAB9-2DCD-4056-B0F3-F30B6A07FD94Q27000805-149A2106-2003-4129-B136-FAF76277A7E2Q30353872-7A38F67C-5F10-4D9E-88C7-14407A9EDCDFQ30429816-20BBCCDC-C115-4F71-9709-0DE2FE14CCE9Q33708690-1AC0954F-38C0-4D67-B985-55551C5CB67AQ33827988-5F80CC15-C94F-422F-9CF9-FC98D3B7A42DQ34016243-74072921-AAF6-4265-9176-8E659EC29657Q34620531-8CA02AAB-45CB-4FE4-97F6-3856CE26494AQ34982478-45B87A32-D84E-4612-BF83-6FFA994BE1C3Q36468087-45FD4C95-0FB8-426D-8B04-7CC369DE8E6DQ36783891-84D7518F-3C03-4A60-8AA0-DD3BDB4BEAF7Q37368688-1CBFF604-89D3-40FB-9C0C-8AC72DCECBF2Q37404241-4356AB27-8EFD-42E6-B08E-9F6F145FFDE3Q37428359-00C84B87-F2D3-424D-88DE-0472E82A84D3Q37801370-8CEDA409-E7C3-41DD-9D34-C0B5600A076FQ37828446-DF8217BC-726B-424F-B9FF-A7CF84C04191Q38031743-DB2831DF-8F6C-4A20-9F38-27891D4444FEQ38071006-93DCBCA3-1E37-4BAF-B9BD-F3C80E6A4C77Q38194649-6ADF161D-E305-49BF-BD0F-13D5B0ECCB20Q38237336-2B858279-C1E1-4297-A29D-12A3AF8C039BQ38582461-46669E9B-CA7A-441B-A9E0-620BF4ACABF6Q38717129-03664D89-5C46-4EFF-8559-94C47C161C92Q39544994-02E1A92A-3214-4FBA-9A89-A47150B92F14Q41248445-F5765BD3-07A9-4002-A31B-E002257752F7Q43138240-8B23B6ED-E655-4310-A6A5-450DC872B6AFQ44468306-0B90C446-AFC9-45CA-B93C-7E4D93317BBAQ50868368-55C2E43B-20C9-46FE-A4DC-DA045E6D35F6Q55326346-9BC2C1EB-A90D-4AC9-BB16-B4D1ED45CF09
P2860
Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cetilistat (ATL-962), a novel ...... t reduction in obese patients.
@ast
Cetilistat (ATL-962), a novel ...... t reduction in obese patients.
@en
type
label
Cetilistat (ATL-962), a novel ...... t reduction in obese patients.
@ast
Cetilistat (ATL-962), a novel ...... t reduction in obese patients.
@en
prefLabel
Cetilistat (ATL-962), a novel ...... t reduction in obese patients.
@ast
Cetilistat (ATL-962), a novel ...... t reduction in obese patients.
@en
P2093
P2860
P356
P1476
Cetilistat (ATL-962), a novel ...... t reduction in obese patients.
@en
P2093
Hickling R
Kopelman P
Rissanen A
P2860
P2888
P304
P356
10.1038/SJ.IJO.0803446
P407
P577
2006-09-05T00:00:00Z
P5875
P6179
1045265939